AJP - Regu Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Regul Integr Comp Physiol 296: R1726-R1734, 2009. First published April 22, 2009; doi:10.1152/ajpregu.90963.2008
0363-6119/09 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
296/6/R1726    most recent
90963.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Uddin, M. N.
Right arrow Articles by Puschett, J. B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Uddin, M. N.
Right arrow Articles by Puschett, J. B.

RECEPTORS AND SIGNALING PATHWAYS

Marinobufagenin causes endothelial cell monolayer hyperpermeability by altering apoptotic signaling

Mohammad N. Uddin,1 Darijana Horvat,1 Ed W. Childs,2 and Jules B. Puschett1

Division of Nephrology and Hypertension, Departments of 1Medicine and 2Surgery, Texas A&M University Health Science Center College of Medicine and Scott & White Memorial Hospital, Temple, Texas

Submitted 26 November 2008 ; accepted in final form 15 April 2009

Marinobufagenin (MBG) is an endogenous mammalian cardiotonic steroid that is involved in the inhibition of the sodium pump Na+/K+-ATPase. Increased plasma levels of MBG have been reported in patients with preeclampsia. MBG increases microvascular barrier permeability in an animal model of preeclampsia. However, the mechanism by which MBG impairs endothelial permeability is unknown. We utilized rat lung microvascular endothelial cells (RLMEC) to examine alterations in MBG-induced monolayer permeability and the effect of MBG on the phosphorylation status of ERK1/2, Jnk, and p38. Apoptosis was evaluated by examining alterations in caspases 3/7, 8, and 9 and annexin-V staining. We also examined the effect of MBG on the endothelial adherens junctions of the RLMEC monolayer. MBG inhibited the proliferation, and increased the monolayer permeability, of RLMEC. These actions of MBG were attenuated by ERK, p38, and pan caspase inhibition. MBG significantly decreased the phosphorylation of ERK1/2 and activated the phosphorylation of Jnk and p38. MBG also significantly increased the expression of caspases 3/7, 8, and 9, indicating the activation of apoptosis. MBG-induced apoptosis signaling was not observed in cells pretreated with a p38 inhibitor. MBG treatment induced the disruption of endothelial cell junctions. This effect was prevented by a pan caspase inhibitor. In conclusion, 1) MBG induced an impairment of RLMEC proliferation; 2) the bufadienolide also caused endothelial hyperpermeability; and 3) these effects of MBG were mediated by the downregulation of ERK1/2, the upregulation of Jnk and p38, by the activation of apoptosis, and by the disruption of endothelial cell junctions.

β-catenin; rat lung microvascular endothelial cells; MAP kinase; caspases; bufodienolide



Address for reprint requests and other correspondence: J. B. Puschett, 2401 South 31st St., Medical Education Bldg., Rm. 407L, Temple, TX 76508 (e-mail: jpuschett{at}swmail.sw.org)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2009 by the American Physiological Society.